JPRN-jRCT2031210042招募中2 期
Phase II study of JTE-051 -Dose finding study in patients with interstitial cystitis
Koretomo Ryosuke0 个研究点目标入组 150 人开始时间: 2021年4月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 75age old（—）
- 性别
- All
入选标准
- •1. Diagnosed with interstitial cystitis or bladder pain syndrome
- •2. Japanese patient aged >=20 and <75 at the time of informed consent
- •3. Satisfied with protocol-defined criteria for NRS average bladder pain score, ICSI score, and daily urinary frequency
排除标准
- •1. Have been received therapies (e.g., transurethral resection/fulguration, intravesical instillation, or hydrodistension) during protocol-specified period
- •2. Have history of augmentation cystoplasty, cystectomy or urinary diversion
- •3. Found to meet protocol-defined conditions determined by screening results (e.g., laboratory tests)
- •4. Presence of severe hepatic diseases
- •5. Presence or history within 5 years of malignancy
研究者
相似试验
未知
2 期
Phase 2 Dose-Finding Study of JTT-305 in Patients with Primary Osteoporosis.JPRN-jRCT2080220803JAPAN TABACCO INC.320
招募中
1 期
Dermal Safety Study of JTE-052atopic dermatitisJPRN-jRCT2031230570Koretomo Ryosuke22
已完成
2 期
A Phase 2 to Evaluate the Dose-Response Relationship and Safety of JTT-751 in Patients with Iron Deficiency AnemiaIron deficiency anemiaJPRN-jRCT2080223256Japan Tobacco Inc.147
进行中（未招募）
1 期
A clinical gene therapy study with hematopoietic stem cells for the treatment of patients suffering from a malignant neoplasm of the central nervous systemGlioblastoma MultiformeEUCTR2018-001404-11-ITGENENTA SCIENCE SR21
进行中（未招募）
不适用
A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction - RESPONDsevere sepsisMedDRA version: 8.1Level: LLTClassification code 10040047Term: SepsisEUCTR2006-002112-99-BEEli Lilly & Company Limited488